Share This Page
Drug Price Trends for NDC 00527-4095
✉ Email this page to a colleague
Average Pharmacy Cost for 00527-4095
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-300-40 MG CAPSULE | 00527-4095-37 | 0.48562 | EACH | 2025-04-23 |
| BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-300-40 MG CAPSULE | 00527-4095-37 | 0.52005 | EACH | 2025-03-19 |
| BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-300-40 MG CAPSULE | 00527-4095-37 | 0.54647 | EACH | 2025-02-19 |
| BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-300-40 MG CAPSULE | 00527-4095-37 | 0.53925 | EACH | 2025-01-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00527-4095
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| No data available in table | |||||||
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Drug NDC: 00527-4095
The pharmaceutical industry is constantly evolving, with drug prices and market trends playing a crucial role in shaping healthcare policies and patient access to medications. In this comprehensive analysis, we'll dive deep into the market dynamics and price projections for the drug with National Drug Code (NDC) 00527-4095, which is a combination of butalbital, acetaminophen, and caffeine.
Understanding the National Drug Code (NDC)
Before we delve into the specifics of NDC 00527-4095, it's essential to understand what an NDC is and why it matters. The National Drug Code is a unique, three-segment number assigned by the U.S. Food and Drug Administration (FDA) to human drugs in the United States. It serves as a universal product identifier for drugs and plays a crucial role in monitoring drug safety, pricing, and distribution.
Composition and Uses of NDC 00527-4095
NDC 00527-4095 is a combination medication containing butalbital, acetaminophen, and caffeine[1]. This drug is typically prescribed for the treatment of tension headaches and is classified as a barbiturate and analgesic combination. The specific formulation includes:
- Butalbital: A barbiturate that helps relax muscle contractions
- Acetaminophen: An analgesic (pain reliever) and antipyretic (fever reducer)
- Caffeine: A stimulant that can enhance the effects of acetaminophen
Current Market Position
As of 2025, the market for combination pain medications like NDC 00527-4095 remains significant, driven by the prevalence of tension headaches and migraines in the general population. However, the landscape is evolving due to concerns about the addictive potential of barbiturates and the push for safer alternatives.
Historical Price Trends
To understand future price projections, it's crucial to examine historical trends. While specific data for NDC 00527-4095 is limited, we can draw insights from overall prescription drug pricing trends:
From January 1, 2022 to January 1, 2023, the average price increase (among NDCs with a price increase) was $589.68 per drug[2].
This significant increase reflects the broader trend of rising prescription drug costs in the United States. However, it's important to note that individual drugs may deviate from this average based on various factors.
Factors Influencing Price Projections
Several key factors are likely to influence the price projections for NDC 00527-4095 in the coming years:
1. Regulatory Environment
The pharmaceutical industry is heavily regulated, and changes in policies can significantly impact drug prices. Recent legislative efforts to control drug prices may put downward pressure on the cost of medications like NDC 00527-4095.
2. Competition from Generics and Alternatives
As patents expire and new treatment options emerge, competition can intensify, potentially leading to price stabilization or even decreases. For combination drugs like NDC 00527-4095, the availability of generic versions or alternative therapies could impact pricing strategies.
3. Manufacturing Costs
Fluctuations in the cost of raw materials, production, and distribution can affect the final price of the drug. Any changes in these areas could lead to price adjustments.
4. Market Demand
The prevalence of tension headaches and the effectiveness of this combination medication will continue to drive demand. However, changing prescribing patterns due to concerns about barbiturate use may influence overall demand.
5. Healthcare Policy Changes
The ongoing debate around healthcare reform in the United States could lead to significant changes in drug pricing policies. Any new legislation aimed at reducing prescription drug costs could impact the price of NDC 00527-4095.
Price Projections for 2025 and Beyond
Based on the available data and industry trends, we can make some educated projections about the price of NDC 00527-4095 for 2025 and the near future:
Short-term Outlook (2025-2026)
In the short term, we might expect to see moderate price increases for NDC 00527-4095, in line with overall prescription drug trends. However, these increases are likely to be tempered by growing scrutiny of drug prices and potential policy interventions.
Medium-term Outlook (2027-2029)
As we move into the medium term, the price trajectory for NDC 00527-4095 may start to flatten or even decrease slightly. This could be driven by:
- Increased competition from generic versions or alternative therapies
- Potential implementation of new drug pricing policies
- Shifts in prescribing patterns away from barbiturate-containing medications
Long-term Outlook (2030 and beyond)
Looking further ahead, the long-term price projections for NDC 00527-4095 are more uncertain. Factors that could influence pricing include:
- Technological advancements in drug manufacturing
- Potential breakthroughs in headache treatment
- Major healthcare policy reforms
Comparative Analysis with Similar Drugs
To provide context for the price projections of NDC 00527-4095, it's helpful to compare it with similar drugs in the market:
-
Other butalbital combinations: Drugs like Fioricet (butalbital/acetaminophen/caffeine) and Fiorinal (butalbital/aspirin/caffeine) may follow similar pricing trends.
-
Non-barbiturate headache medications: Triptans and newer CGRP antagonists for migraine treatment could influence the market position and pricing of NDC 00527-4095.
-
Over-the-counter alternatives: The availability and pricing of OTC pain relievers may indirectly affect the perceived value and pricing of prescription options like NDC 00527-4095.
Impact of Recent Policy Changes
Recent policy changes have the potential to significantly impact drug pricing, including that of NDC 00527-4095:
Medicare Drug Price Negotiation Program
The implementation of the Medicare Drug Price Negotiation Program, part of the Inflation Reduction Act, could have far-reaching effects on prescription drug prices[10]. While NDC 00527-4095 may not be directly affected if it's not among the highest-expenditure drugs for Medicare, the program could set a precedent for broader price negotiations in the pharmaceutical industry.
Inflation Rebate Program
The Inflation Rebate Program, which requires drug manufacturers to pay rebates to Medicare if they increase prices faster than the rate of inflation, could help keep price increases for drugs like NDC 00527-4095 in check[4].
Market Strategies for Pharmaceutical Companies
In light of these projections and market forces, pharmaceutical companies may adopt various strategies to maintain profitability while navigating pricing pressures:
-
Value-based pricing: Demonstrating the drug's effectiveness and value to payers and patients to justify pricing.
-
Cost optimization: Improving manufacturing processes to reduce production costs.
-
Diversification: Developing new formulations or combination therapies to expand the product line.
-
Patient assistance programs: Offering discounts or copay assistance to maintain access and market share.
Implications for Healthcare Providers and Patients
The price projections for NDC 00527-4095 have several implications for healthcare providers and patients:
For Healthcare Providers:
- Need to stay informed about pricing trends to make cost-effective prescribing decisions
- Potential for increased scrutiny of barbiturate prescriptions
- Importance of discussing treatment costs with patients
For Patients:
- Potential for out-of-pocket cost fluctuations
- Importance of discussing alternative treatment options with healthcare providers
- Need to stay informed about insurance coverage and patient assistance programs
Future of Headache Treatment and Its Impact on NDC 00527-4095
The future of headache treatment could significantly influence the market position and pricing of NDC 00527-4095. Emerging trends include:
- Personalized medicine approaches: Tailoring treatments based on genetic and biomarker profiles
- Non-pharmacological interventions: Increased focus on lifestyle modifications and alternative therapies
- Digital health solutions: Apps and devices for headache tracking and management
As these trends evolve, they may impact the demand for traditional combination medications like NDC 00527-4095, potentially influencing its pricing and market share.
Key Takeaways
- NDC 00527-4095, a combination of butalbital, acetaminophen, and caffeine, faces a complex market environment with various factors influencing its price projections.
- Short-term moderate price increases are expected, with potential flattening or decreases in the medium to long term due to competition and policy interventions.
- Recent policy changes, including the Medicare Drug Price Negotiation Program and Inflation Rebate Program, may help control price increases.
- The future of headache treatment, including personalized medicine and digital health solutions, could impact the long-term market position of NDC 00527-4095.
- Healthcare providers and patients need to stay informed about pricing trends and alternative treatment options to make cost-effective decisions.
FAQs
-
Q: How often do drug prices typically change? A: Drug prices can change at any time, but many manufacturers adjust prices annually or semi-annually. However, significant market events or policy changes can lead to more frequent adjustments.
-
Q: Are there any generic alternatives to NDC 00527-4095? A: Yes, there are generic versions of butalbital/acetaminophen/caffeine combinations available. These generics typically offer a more cost-effective option compared to brand-name versions.
-
Q: How might the increasing focus on opioid alternatives affect the pricing of NDC 00527-4095? A: As healthcare providers seek alternatives to opioids for pain management, drugs like NDC 00527-4095 may see increased scrutiny due to the barbiturate component. This could potentially lead to decreased demand and impact pricing strategies.
-
Q: What role do Pharmacy Benefit Managers (PBMs) play in determining the price of drugs like NDC 00527-4095? A: PBMs negotiate prices with drug manufacturers and can influence which drugs are covered by insurance plans. Their negotiations and formulary decisions can significantly impact the final price patients pay for medications like NDC 00527-4095.
-
Q: How can patients find the best price for NDC 00527-4095? A: Patients can compare prices at different pharmacies, use prescription discount cards, check for manufacturer coupons, and discuss generic alternatives with their healthcare provider to find the best price for NDC 00527-4095.
Sources cited: [1] https://fda.report/NDC/0527-1695 [2] https://aspe.hhs.gov/sites/default/files/documents/0cdd88059165eef3bed1fc587a0fd68a/aspe-drug-price-tracking-brief.pdf [4] https://pubmed.ncbi.nlm.nih.gov/37094296/ [10] https://www.drugpatentwatch.com/p/drug-price/ndc/70752-0147
More… ↓
